KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clorox (CLX) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Clorox (CLX) over the last 15 years, with Sep 2025 value amounting to -$40.0 million.

  • Clorox's Change in Accured Expenses rose 70.80% to -$40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.0 million, marking a year-over-year increase of 80.58%. This contributed to the annual value of -$124.0 million for FY2025, which is 11.43% up from last year.
  • Latest data reveals that Clorox reported Change in Accured Expenses of -$40.0 million as of Q3 2025, which was down 8.11% from -$37.0 million recorded in Q2 2025.
  • Clorox's 5-year Change in Accured Expenses high stood at $217.0 million for Q2 2021, and its period low was -$138.0 million during Q3 2023.
  • In the last 3 years, Clorox's Change in Accured Expenses had a median value of -$20.0 million in 2024 and averaged -$8.5 million.
  • As far as peak fluctuations go, Clorox's Change in Accured Expenses slumped by 1,233.33% in 2021, and later soared by 256.76% in 2023.
  • Over the past 5 years, Clorox's Change in Accured Expenses (Quarterly) stood at -$34.0 million in 2021, then climbed by 23.53% to -$26.0 million in 2022, then rose by 3.85% to -$25.0 million in 2023, then spiked by 96.00% to -$1.0 million in 2024, then spiked by 70.80% to -$40.0 million in 2025.
  • Its Change in Accured Expenses stands at -$40.0 million for Q3 2025, versus -$37.0 million for Q2 2025 and $51.0 million for Q1 2025.